RT Journal Article
SR Electronic
T1 Biodistribution and Radiation Dosimetry of the Dopamine Transporter Ligand [<sup>18</sup>F]FECNT
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 376
OP 381
VO 42
IS 2
A1 Todd A. Deterding
A1 John R. Votaw
A1 Chris K. Wang
A1 Dennis Eshima
A1 Lori Eshima
A1 Robert Keil
A1 Eugene Malveaux
A1 Clinton D. Kilts
A1 Mark M. Goodman
A1 John M. Hoffman
YR 2001
UL http://jnm.snmjournals.org/content/42/2/376.abstract
AB 18F-labeled 2 β-carbomethoxy-3β-(4-chlorophenyl)-8-(−2-fluoroethyl)nortropane ([18F]FECNT) is a recently developed dopamine transporter ligand with potential applications in patients with Parkinson’s disease and cocaine addiction. Methods: Estimates of the effective dose equivalent and doses for specific organs were made using biodistribution data from 16 Sprague-Dawley rats and nine rhesus monkeys. PET images from two rhesus monkeys were used to calculate the residence time for the basal ganglia. The computer program MIRDOSE3 was used to calculate the dosimetry according to the methodology recommended by MIRD. Results: The basal ganglia were the targeted tissues receiving the highest dose, 0.11 mGy/MBq (0.39 rad/mCi). The effective dose equivalent was 0.018 mSv/MBq (0.065 rem/mCi), and the effective dose was 0.016 mSv/MBq (0.058 rem/mCi). Conclusion: Our data show that a 185-MBq (5-mCi) injection of [18F]FECNT leads to an estimated effective dose of 3 mSv (0.3 rem) and an estimated dose to the target organ or tissue of 19.4 mGy (1.93 rad).